AU2017250809B2 - Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer - Google Patents

Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer Download PDF

Info

Publication number
AU2017250809B2
AU2017250809B2 AU2017250809A AU2017250809A AU2017250809B2 AU 2017250809 B2 AU2017250809 B2 AU 2017250809B2 AU 2017250809 A AU2017250809 A AU 2017250809A AU 2017250809 A AU2017250809 A AU 2017250809A AU 2017250809 B2 AU2017250809 B2 AU 2017250809B2
Authority
AU
Australia
Prior art keywords
dose
hu5f9
priming
agent
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017250809A
Other languages
English (en)
Other versions
AU2017250809A1 (en
Inventor
Mark P. Chao
Jie Liu
Ravindra Majeti
Jens-Peter VOLKMER
Irving L. Weissman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2017250809A1 publication Critical patent/AU2017250809A1/en
Application granted granted Critical
Publication of AU2017250809B2 publication Critical patent/AU2017250809B2/en
Priority to AU2024203396A priority Critical patent/AU2024203396A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017250809A 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer Active AU2017250809B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203396A AU2024203396A1 (en) 2016-04-15 2024-05-22 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US62/323,330 2016-04-15
US201662427679P 2016-11-29 2016-11-29
US62/427,679 2016-11-29
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203396A Division AU2024203396A1 (en) 2016-04-15 2024-05-22 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Publications (2)

Publication Number Publication Date
AU2017250809A1 AU2017250809A1 (en) 2018-10-25
AU2017250809B2 true AU2017250809B2 (en) 2024-02-29

Family

ID=60042716

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017250809A Active AU2017250809B2 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
AU2024203396A Pending AU2024203396A1 (en) 2016-04-15 2024-05-22 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203396A Pending AU2024203396A1 (en) 2016-04-15 2024-05-22 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Country Status (12)

Country Link
US (3) US11472878B2 (enExample)
EP (3) EP3442578B1 (enExample)
JP (3) JP7532009B2 (enExample)
KR (3) KR20240016445A (enExample)
CN (3) CN115350276A (enExample)
AU (2) AU2017250809B2 (enExample)
CA (1) CA3019676A1 (enExample)
ES (1) ES2909835T3 (enExample)
PL (1) PL3442578T3 (enExample)
PT (1) PT3442578T (enExample)
SI (1) SI3442578T1 (enExample)
WO (1) WO2017181033A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CN111247172B (zh) 2017-10-18 2023-11-14 四十七公司 基于抗cd47剂的卵巢癌疗法
EP4129336B1 (en) 2018-02-12 2025-05-07 Forty Seven, LLC Anti-cd47 agent-based treatment of cd20-positive cancer
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
MY205933A (en) 2018-09-27 2024-11-21 Celgene Corp Sirp-alpha binding proteins and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
PL3817773T3 (pl) 2018-11-26 2024-10-28 Forty Seven, Inc. Humanizowane przeciwciała przeciwko c-kit
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
KR20220113353A (ko) 2019-09-18 2022-08-12 람캅 바이오 알파 에이지 Ceacam5 및 cd3에 대한 이중특이적 항체
US11702474B2 (en) 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation
WO2022076928A1 (en) * 2020-10-09 2022-04-14 Sana Biotechnology, Inc. METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT
US12071481B2 (en) 2020-12-23 2024-08-27 D-10 Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
EP4274853A4 (en) * 2021-01-05 2024-12-04 National Institute Of Biological Sciences, Beijing BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056515T4 (da) 2008-01-15 2025-10-20 Univ Leland Stanford Junior Fremgangsmåde til at manipulere fagocytose medieret af cd47
CA2714006A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
ES2616010T3 (es) * 2010-05-14 2017-06-09 The Board Of Trustees Of The Leland Stanford Junior University Anticuerpos monoclonales humanizados y quiméricos a CD47
CN104136037B (zh) 2012-01-17 2018-02-23 小利兰·斯坦福大学托管委员会 高亲和力SIRP‑α试剂
HRP20191500T1 (hr) 2012-02-06 2019-11-29 Inhibrx Inc Protutijela protiv cd47 i postupci njihove upotrebe
BR112015018851A2 (pt) 2013-02-06 2017-07-18 Inhibrx Llc anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos
RU2015145610A (ru) 2013-03-27 2017-05-04 Дженентек, Инк. Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
ES2898627T3 (es) 2013-04-29 2022-03-08 Univ Leland Stanford Junior Uso de agentes anti-CD47 para mejorar la inmunización
WO2015050983A1 (en) 2013-10-01 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
CN108025060A (zh) * 2014-06-08 2018-05-11 瑞美德生物医药科技有限公司 使用胰高血糖素受体拮抗性抗体治疗1型糖尿病的方法
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
EP3204420B1 (en) * 2014-10-10 2020-09-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to eliminate cancer stem cells by targeting cd47
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIE LIU ET AL: PLOS ONE, vol. 10, no. 9, 21 September 2015 (2015-09-21), pages 1 - 23, XP055223677, Retrieved from the Internet DOI: 10.1371/journal.pone.0137345 *

Also Published As

Publication number Publication date
JP7442591B2 (ja) 2024-03-04
ES2909835T3 (es) 2022-05-10
EP3442578B1 (en) 2022-02-09
KR102505253B1 (ko) 2023-03-02
JP7532009B2 (ja) 2024-08-13
KR20180134367A (ko) 2018-12-18
US20230406923A1 (en) 2023-12-21
US11472878B2 (en) 2022-10-18
KR20240016445A (ko) 2024-02-06
CN117695387A (zh) 2024-03-15
US20230068235A1 (en) 2023-03-02
AU2024203396A1 (en) 2024-06-06
CN109152837A (zh) 2019-01-04
JP2019515899A (ja) 2019-06-13
CN115350276A (zh) 2022-11-18
JP2022172278A (ja) 2022-11-15
EP3442578A1 (en) 2019-02-20
EP3442578A4 (en) 2019-04-10
SI3442578T1 (sl) 2022-05-31
KR20230035435A (ko) 2023-03-13
JP2024059764A (ja) 2024-05-01
US20190106491A1 (en) 2019-04-11
AU2017250809A1 (en) 2018-10-25
CA3019676A1 (en) 2017-10-19
EP4074339A1 (en) 2022-10-19
PT3442578T (pt) 2022-05-19
WO2017181033A1 (en) 2017-10-19
PL3442578T3 (pl) 2022-06-20
US11718670B2 (en) 2023-08-08
EP4349412A3 (en) 2024-06-12
EP4349412A2 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
US11718670B2 (en) Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
AU2020264334B2 (en) Targeted therapy for small cell lung cancer
US11891450B2 (en) Anti-CD47 agent-based treatment of CD20-positive cancer
AU2014238105B2 (en) Methods for achieving therapeutically effective doses of anti-CD47 agents
HK40107887A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40080891A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40082292A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40086849A (en) Anti-cd47 agent-based treatment of cd20-positive cancer
WO2023185720A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)